Johnson & Johnson (NYSE:JNJ) Shares Sold by Community Bank N.A.

Community Bank N.A. reduced its stake in shares of Johnson & Johnson (NYSE:JNJ) by 3.9% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 43,067 shares of the company’s stock after selling 1,727 shares during the quarter. Johnson & Johnson accounts for approximately 0.9% of Community Bank N.A.’s investment portfolio, making the stock its 24th biggest holding. Community Bank N.A.’s holdings in Johnson & Johnson were worth $6,750,000 at the end of the most recent quarter.

Several other institutional investors have also recently modified their holdings of the company. Tokio Marine Asset Management Co. Ltd. lifted its position in Johnson & Johnson by 2.4% during the fourth quarter. Tokio Marine Asset Management Co. Ltd. now owns 56,732 shares of the company’s stock valued at $8,892,000 after purchasing an additional 1,343 shares during the period. Atria Wealth Solutions Inc. boosted its stake in shares of Johnson & Johnson by 2.8% in the fourth quarter. Atria Wealth Solutions Inc. now owns 162,847 shares of the company’s stock worth $25,525,000 after buying an additional 4,497 shares during the last quarter. Capital Advisors Ltd. LLC grew its holdings in Johnson & Johnson by 6.4% during the fourth quarter. Capital Advisors Ltd. LLC now owns 3,454 shares of the company’s stock worth $541,000 after acquiring an additional 209 shares during the period. Wynn Capital LLC acquired a new position in Johnson & Johnson in the fourth quarter valued at approximately $1,910,000. Finally, South Dakota Investment Council lifted its holdings in Johnson & Johnson by 8.1% in the fourth quarter. South Dakota Investment Council now owns 180,203 shares of the company’s stock valued at $28,245,000 after acquiring an additional 13,525 shares during the period. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Johnson & Johnson

In other Johnson & Johnson news, major shareholder & Johnson Johnson sold 3,725 shares of the business’s stock in a transaction dated Friday, February 16th. The shares were sold at an average price of $25.81, for a total value of $96,142.25. Following the transaction, the insider now directly owns 4,099,575 shares in the company, valued at approximately $105,810,030.75. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 59,397 shares of the stock in a transaction dated Friday, February 9th. The shares were sold at an average price of $156.27, for a total transaction of $9,281,969.19. Following the completion of the transaction, the executive vice president now owns 141,416 shares of the company’s stock, valued at $22,099,078.32. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, major shareholder & Johnson Johnson sold 3,725 shares of the business’s stock in a transaction that occurred on Friday, February 16th. The shares were sold at an average price of $25.81, for a total transaction of $96,142.25. Following the completion of the sale, the insider now directly owns 4,099,575 shares in the company, valued at $105,810,030.75. The disclosure for this sale can be found here. 0.16% of the stock is currently owned by insiders.

Johnson & Johnson Stock Up 0.5 %

JNJ stock opened at $146.84 on Tuesday. The company has a market cap of $353.85 billion, a price-to-earnings ratio of 9.15, a PEG ratio of 2.41 and a beta of 0.53. The firm has a 50-day moving average of $155.07 and a two-hundred day moving average of $155.23. Johnson & Johnson has a 12 month low of $143.13 and a 12 month high of $175.97. The company has a current ratio of 1.16, a quick ratio of 0.91 and a debt-to-equity ratio of 0.38.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Tuesday, April 16th. The company reported $2.71 EPS for the quarter, beating the consensus estimate of $2.64 by $0.07. The firm had revenue of $21.38 billion during the quarter, compared to analysts’ expectations of $21.39 billion. Johnson & Johnson had a return on equity of 36.43% and a net margin of 45.26%. The business’s revenue for the quarter was up 2.3% on a year-over-year basis. During the same quarter last year, the firm earned $2.68 earnings per share. As a group, analysts forecast that Johnson & Johnson will post 10.65 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 4th. Stockholders of record on Tuesday, May 21st will be given a dividend of $1.24 per share. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.19. The ex-dividend date of this dividend is Monday, May 20th. This represents a $4.96 annualized dividend and a dividend yield of 3.38%. Johnson & Johnson’s payout ratio is presently 29.68%.

Analysts Set New Price Targets

A number of analysts recently issued reports on the stock. Cantor Fitzgerald reissued an “overweight” rating and set a $215.00 price target on shares of Johnson & Johnson in a report on Monday, April 15th. Morgan Stanley lowered their target price on shares of Johnson & Johnson from $168.00 to $167.00 and set an “equal weight” rating on the stock in a research note on Wednesday, April 17th. Bank of America cut their price target on Johnson & Johnson from $180.00 to $170.00 and set a “neutral” rating for the company in a research note on Wednesday, April 17th. Royal Bank of Canada lowered their price target on Johnson & Johnson from $181.00 to $175.00 and set an “outperform” rating on the stock in a research report on Wednesday, April 17th. Finally, HSBC upgraded Johnson & Johnson from a “hold” rating to a “buy” rating and boosted their price objective for the company from $169.00 to $170.00 in a research report on Thursday, April 18th. Seven investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $175.86.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.